American Conference Institute's 6th National Conference on Managing Legal Risks in Structuring & Conducting Clinical Trials
27 February 2007
The American Conference Institute’s 6th National Conference on Managing Legal Risks in Structuring & Conducting Clinical Trials will take place February 27-28, 2007 at the Roosevelt Hotel in New York. Legal and compliance experts from pharmaceutical and medical device companies, Contract Research Organizations (CROs), and hospital and research institutions, as well as attorneys will provide an intensive and thorough review of the critical issues that arise in ensuring proper management of protocols, contracts, consents, and other documents.
On February 27, Securities Litigation, Enforcement & Regulation senior counsel Elizabeth Gray will present Reacting to Scrutiny of Clinical Trial Disclosures by the SEC which will review the following:
- How FDA and SEC cooperation (Referral Process and Centralized Procedures) have affected scrutiny of clinical trial disclosures
- Complying with SEC reporting requirements pre- and post-approval
- Reconciling FDA/SEC disclaimer requirements
- Factoring in recent enforcement activities by the SEC and FDA
- Lessons learned from ImClone, TKT, ICN, and NY Executive Law 63(12)
- Disclosing clinical trial information that has been made available to the FDA but not publicly disclosed
- Determining what FDA actions to disclose and how to disclose them for accurate interpretation by the securities market
- Alleviating securities concerns: whether databank entries constitute “forward-looking statements” for investor reliance
- Controlling and monitoring material inside information
Related Insights
18 February 2025
Labor & Employment Law Perspectives
Noncompete Bans – Next Up: Ohio
This month, Ohio joined the list of states with pending legislation to ban noncompetes. With the FTC noncompete ban blocked on a nationwide basis last year, Ohio lawmakers introduced a bill on February 5, 2025, that would ban noncompete contracts as a condition of employment in the state.
18 February 2025
DEA Delays Final Buprenorphine Rule
The Department of Health and Human Services and the Drug Enforcement Administration have delayed the effective date of the final rule regarding telemedicine prescribing of buprenorphine to March 21, 2025, and have requested public comments on the rule.
17 February 2025
Foley Viewpoints
6 Steps to Manage Tariff Risks in a Trade War
As Trump seeks to raise U.S. tariffs (which currently tend to be among the lowest worldwide), manufacturers, distributors, retailers, and other companies that frequently import must determine the best strategy to deal with the resulting uncertainties.